Actively Recruiting
Stress-reducing Intervention in Urothelial Carcinoma
Led by Comenius University · Updated on 2024-02-21
50
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated with chemotherapy based on cisplatin in neoadjuvant setting followed by local therapy (standard of care, SOC) compared to SOC alone.
CONDITIONS
Official Title
Stress-reducing Intervention in Urothelial Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years
- Biopsy-proven muscle-infiltrating urothelial bladder carcinoma (including variants)
- No prior chemotherapy treatment
- No previous malignancy except basal-cell carcinoma of the skin within last 5 years
- Adequate kidney function with creatinine clearance over 60 ml/min
- Absolute granulocyte count of 1,500/mm3 or higher and platelet count of 100,000/mm3 or higher
- Bilirubin level at or below 1.5 times the upper normal limit
- Adequate liver function
- Basic computer skills
- Signed informed consent
You will not qualify if you...
- Diabetes mellitus with symptomatic neuropathy
- Use of antiarrhythmic drugs, opiates, or antidepressants
- Implanted permanent pacemaker
- HIV infection
- Not meeting inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Institute
Bratislava, Slovakia, 83310
Actively Recruiting
Research Team
L
Luba Hunáková
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here